Triglyceride-Glucose and TGI-BMI Indices Compared With HOMA-IR

NCT ID: NCT07260201

Last Updated: 2025-12-03

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-12-01
• Study Completion Date: 2025-10-27

Brief Summary

Insulin resistance plays a key role in the development of type 2 diabetes, metabolic syndrome, and heart disease. The most common way to measure insulin resistance is the HOMA-IR index, but it requires fasting insulin tests, which are not always available in clinical practice.

This study aims to assess two simpler and more accessible alternatives: the triglyceride-glucose index (TGI) and its body mass index-adjusted version (TGI-BMI). Data from 150 adult patients were analyzed retrospectively and divided into groups according to their insulin resistance status. Standard laboratory and body measurements were compared between groups, and statistical analyses were used to determine how well TGI and TGI-BMI identify insulin resistance.

The results showed that both TGI and TGI-BMI were closely related to insulin resistance and demonstrated high diagnostic accuracy, similar to HOMA-IR. The TGI-BMI index was particularly effective in individuals with obesity. These findings suggest that TGI and TGI-BMI could serve as practical, low-cost alternatives to HOMA-IR for evaluating insulin resistance in clinical and population settings where insulin testing is not routinely available.

Detailed Description

Insulin resistance (IR) is a central feature of metabolic and cardiovascular disorders, yet the routine measurement of fasting insulin required for HOMA-IR limits its clinical applicability. The triglyceride-glucose index (TGI) and its body mass index-adjusted form (TGI-BMI) have emerged as simple, cost-effective surrogates that rely only on standard biochemical data.

This retrospective study analyzed data from 150 adults evaluated at Hisar Intercontinental Hospital. Participants were categorized into insulin-resistant (HOMA-IR > 2.5) and non-resistant (HOMA-IR < 2.5) groups. Anthropometric and biochemical variables were obtained from medical records. TGI and TGI-BMI values were calculated for each participant, and comparisons were made between groups. Correlation and receiver operating characteristic (ROC) analyses were used to determine the relationship and diagnostic accuracy of these indices relative to HOMA-IR.

The study aims to validate TGI and TGI-BMI as reliable, low-cost indicators of insulin resistance applicable in both clinical and epidemiological settings, especially in laboratories where insulin assays are unavailable. The findings may contribute to improved screening and risk assessment strategies in metabolic disease management.

Conditions

Insulin Resistance; Obesity Type 2 Diabetes Mellitus

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Group/Cohort 1 Label: Non-Insulin Resistant (Non-IR) Group

Group 1 - Non-Insulin Resistant (Non-IR) Group

Participants with HOMA-IR values below 2.5, classified as non-insulin resistant. Anthropometric and biochemical data (including fasting glucose, triglycerides, and BMI) were analyzed retrospectively to calculate TGI and TGI-BMI indices.

No interventions assigned to this group

Group/Cohort 2 Label: Insulin Resistant (IR) Group

Group 2 - Insulin Resistant (IR) Group

Participants with HOMA-IR values greater than 2.5, classified as insulin resistant. Anthropometric and biochemical measurements were reviewed from medical records, and TGI and TGI-BMI indices were compared with those of the Non-IR group.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Eligible participants were adults aged 18-65 years with complete fasting biochemical and anthropometric data. Only patients who were not receiving antidiabetic medications at the time of evaluation were included.

Exclusion Criteria

• Patients were excluded if they had any of the following:

• Known endocrine disorders (e.g., thyroid dysfunction, Cushing's syndrome)
• Chronic kidney or liver disease
• Active infection or systemic inflammatory disease
• Ongoing use of medications known to affect glucose or lipid metabolism (e.g., corticosteroids, statins, metformin, or insulin)
• Incomplete or missing laboratory data

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hisar Intercontinental Hospital

OTHER

Sponsor Role: lead

Responsible Party

Bekir Sami Uyanık

Professor of Clinical Biochemistry, Hisar Intercontinental Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Bekir Sami Uyanık, MD, Prof

Role: PRINCIPAL_INVESTIGATOR

Hisar Intercontinental Hospital

Selami Aydin, MD

Role: STUDY_DIRECTOR

Hisar Intercontinental Hospital

Süleyman İpekci, Prof

Role: STUDY_CHAIR

Hisar Intercontinental Hospital and Atlas University

Locations

Hisar Intercontinental Hospital

Istanbul, Umraniye, Turkey (Türkiye)

Countries

Turkey (Türkiye)

Study Documents

Document Type: Individual participant data will not be shared because the study is retrospective and based on anonymized medical records.

This publication provides background evidence supporting the evaluation of triglyceride-glucose-based indices as markers of insulin resistance.

View Document

Related Links

https://pubmed.ncbi.nlm.nih.gov/40589514/

This publication supports the present study by demonstrating that the triglyceride-glucose (TyG) index is independently associated with an increased risk of diabetes, even among individuals with normal fasting triglyceride and glucose levels. It provides

Other Identifiers

HIH 2025 HOMA IR

Identifier Type: -

Identifier Source: org_study_id